TD Asset Management Inc Decreases Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Key Points

• TD Asset Management Inc significantly reduced its stake in Oruka Therapeutics by 51.7%, now holding 45,876 shares valued at approximately $471,000.
• Despite the decrease by TD Asset Management, several other institutions such as FMR LLC and Vanguard Group Inc. increased their holdings in Oruka Therapeutics, with Vanguard raising its stake by over 4,161%.
• Analysts have a generally positive outlook on Oruka Therapeutics, with a consensus rating of "Buy" and a target price of $40.38, influenced by multiple buy ratings from research firms.

TD Asset Management Inc cut its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 51.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,876 shares of the company's stock after selling 49,200 shares during the quarter. TD Asset Management Inc owned 0.12% of Oruka Therapeutics worth $471,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. FMR LLC raised its stake in shares of Oruka Therapeutics by 17.7% during the fourth quarter. FMR LLC now owns 5,512,300 shares of the company's stock worth $106,883,000 after acquiring an additional 830,000 shares in the last quarter. Fairmount Funds Management LLC grew its holdings in shares of Oruka Therapeutics by 5.0% in the fourth quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock worth $65,382,000 after purchasing an additional 160,000 shares during the last quarter. VR Adviser LLC grew its holdings in shares of Oruka Therapeutics by 6.5% in the fourth quarter. VR Adviser LLC now owns 3,285,620 shares of the company's stock worth $63,708,000 after purchasing an additional 200,000 shares during the last quarter. RTW Investments LP grew its holdings in shares of Oruka Therapeutics by 5.1% in the fourth quarter. RTW Investments LP now owns 1,945,649 shares of the company's stock worth $37,726,000 after purchasing an additional 95,001 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after acquiring an additional 1,572,853 shares in the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ORKA. BTIG Research began coverage on shares of Oruka Therapeutics in a report on Thursday, May 22nd. They issued a "buy" rating on the stock. HC Wainwright reissued a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Wednesday, July 23rd. Wedbush reissued an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Monday, July 21st. Finally, Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, June 22nd. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $40.38.

Oruka Therapeutics Price Performance

ORKA opened at $14.30 on Tuesday. The stock has a 50-day moving average price of $12.82 and a 200-day moving average price of $11.38. The firm has a market cap of $535.39 million, a PE ratio of -3.17 and a beta of -0.35. Oruka Therapeutics, Inc. has a 1 year low of $5.49 and a 1 year high of $52.32.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. As a group, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.